MXPA04001230A - Uso de inhibidores de il-18 en desordenes de hipersensibilidad. - Google Patents

Uso de inhibidores de il-18 en desordenes de hipersensibilidad.

Info

Publication number
MXPA04001230A
MXPA04001230A MXPA04001230A MXPA04001230A MXPA04001230A MX PA04001230 A MXPA04001230 A MX PA04001230A MX PA04001230 A MXPA04001230 A MX PA04001230A MX PA04001230 A MXPA04001230 A MX PA04001230A MX PA04001230 A MXPA04001230 A MX PA04001230A
Authority
MX
Mexico
Prior art keywords
inhibitors
hypersensitivity disorders
hypersensitivity
disorders
medicament
Prior art date
Application number
MXPA04001230A
Other languages
English (en)
Inventor
Kosco-Vilbois Marie
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA04001230A publication Critical patent/MXPA04001230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere al uso de inhibidores de IL-18 en la preparacion de un medicamento para tratamiento y/o prevencion de desordenes de hipersensibilidad, y en particular de hipersensibilidad de tipo retardada.
MXPA04001230A 2001-08-10 2002-08-01 Uso de inhibidores de il-18 en desordenes de hipersensibilidad. MXPA04001230A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118811 2001-08-10
EP02100735 2002-06-20
PCT/EP2002/008591 WO2003013577A2 (en) 2001-08-10 2002-08-01 Use of il-18 inhibitors in hypersensitivity disorders

Publications (1)

Publication Number Publication Date
MXPA04001230A true MXPA04001230A (es) 2004-05-27

Family

ID=26076673

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001230A MXPA04001230A (es) 2001-08-10 2002-08-01 Uso de inhibidores de il-18 en desordenes de hipersensibilidad.

Country Status (27)

Country Link
US (1) US20040247598A1 (es)
EP (1) EP1423138B1 (es)
JP (1) JP4301942B2 (es)
KR (1) KR20040030948A (es)
CN (1) CN100500210C (es)
AR (1) AR035274A1 (es)
AU (1) AU2002331376B2 (es)
BR (1) BRPI0211827B8 (es)
CA (1) CA2456247C (es)
CY (1) CY1116137T1 (es)
DK (1) DK1423138T3 (es)
EA (1) EA006745B1 (es)
ES (1) ES2533253T3 (es)
HK (1) HK1069780A1 (es)
HR (1) HRP20040071B1 (es)
HU (1) HU230377B1 (es)
IL (2) IL160230A0 (es)
ME (1) ME00547B (es)
MX (1) MXPA04001230A (es)
NO (1) NO335688B1 (es)
PL (1) PL227130B1 (es)
PT (1) PT1423138E (es)
RS (1) RS52224B (es)
SI (1) SI1423138T1 (es)
UA (1) UA78516C2 (es)
WO (1) WO2003013577A2 (es)
ZA (1) ZA200400442B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003927A1 (ja) * 2004-06-30 2006-01-12 Atsuo Sekiyama 非炎症性ストレス応答の指標剤およびその利用
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
ES2514495T3 (es) 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
CN103458904B (zh) * 2010-12-16 2016-09-28 株式会社明治 格氏乳杆菌的菌体级分在制造用于减轻迟发型变态反应的组合物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE69925581T2 (de) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
BR9816013A (pt) * 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
WO2000071719A1 (en) * 1999-05-20 2000-11-30 Hyseq, Inc. Interleukin-1 hy2 materials and methods
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
NO20040370L (no) 2004-03-23
SI1423138T1 (sl) 2015-04-30
HRP20040071B1 (hr) 2015-08-28
HU230377B1 (hu) 2016-03-29
BRPI0211827B1 (pt) 2019-07-23
AR035274A1 (es) 2004-05-05
WO2003013577A2 (en) 2003-02-20
PL227130B1 (pl) 2017-10-31
HK1069780A1 (en) 2005-06-03
EP1423138B1 (en) 2014-12-24
JP2005501080A (ja) 2005-01-13
KR20040030948A (ko) 2004-04-09
HRP20040071A2 (en) 2004-10-31
CA2456247A1 (en) 2003-02-20
HUP0401323A2 (hu) 2004-10-28
CY1116137T1 (el) 2017-02-08
JP4301942B2 (ja) 2009-07-22
IL160230A (en) 2014-11-30
NO335688B1 (no) 2015-01-19
YU11904A (sh) 2006-08-17
ES2533253T3 (es) 2015-04-08
CA2456247C (en) 2013-09-10
CN100500210C (zh) 2009-06-17
EA200400296A1 (ru) 2004-06-24
BR0211827A (pt) 2004-08-31
US20040247598A1 (en) 2004-12-09
WO2003013577A3 (en) 2003-09-25
HUP0401323A3 (en) 2006-01-30
EP1423138A2 (en) 2004-06-02
CN1568193A (zh) 2005-01-19
ZA200400442B (en) 2005-03-30
UA78516C2 (en) 2007-04-10
PL368231A1 (en) 2005-03-21
DK1423138T3 (en) 2015-02-23
PT1423138E (pt) 2015-02-09
RS52224B (sr) 2012-10-31
AU2002331376B2 (en) 2007-06-14
ME00547B (me) 2011-12-20
BRPI0211827B8 (pt) 2021-05-25
EA006745B1 (ru) 2006-04-28
IL160230A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
IL164211A (en) Il-18 inhibitors in peripheral vascular diseases of the extremities
WO2004041269A3 (en) New use for pharmaceutical composition
EP1379232A4 (en) N-ACETYLCYSTEIN COMPOSITION AND METHODS FOR TREATING AND PREVENTING TOXICITY OF MEDICAMENTS
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
HK1081861A1 (en) New synergistic combination comprising roflumilast and formoterol
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HK1082923A1 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
MXPA03010743A (es) Uso de inhibidores de il-18 para el tratamiento o prevencion de lesiones del sistema nervioso central.
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
SI1408966T1 (sl) Sinergistične farmacevtske kombinacije za preprečevanje ali zdravljenje diabetesa

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration